Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $32.75.

YMAB has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Protalix Biotherapeutics in a research note on Monday, June 10th. Cowen reiterated a “buy” rating on shares of Ovid Therapeutics in a report on Monday, July 1st. Finally, Zacks Investment Research upgraded shares of ZovioInc . from a “sell” rating to a “hold” rating in a report on Sunday.

Shares of NASDAQ:YMAB traded up $0.09 during trading on Wednesday, reaching $22.96. The company had a trading volume of 1,130 shares, compared to its average volume of 235,489. The business’s fifty day moving average is $21.82. The firm has a market cap of $782.01 million and a price-to-earnings ratio of -15.27. Y-mAbs Therapeutics has a twelve month low of $15.17 and a twelve month high of $31.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.30 and a quick ratio of 13.30.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.07). On average, research analysts forecast that Y-mAbs Therapeutics will post -1.95 EPS for the current year.

In related news, insider Thomas Gad sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $22.40, for a total value of $89,600.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 28,000 shares of company stock worth $592,880 over the last quarter. Insiders own 38.40% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Citigroup Inc. acquired a new position in Y-mAbs Therapeutics in the 4th quarter valued at approximately $37,000. BNP Paribas Arbitrage SA acquired a new position in Y-mAbs Therapeutics in the 1st quarter valued at approximately $38,000. American International Group Inc. acquired a new position in Y-mAbs Therapeutics in the 4th quarter valued at approximately $93,000. Bank of America Corp DE increased its stake in Y-mAbs Therapeutics by 3,056.5% in the 4th quarter. Bank of America Corp DE now owns 6,029 shares of the company’s stock valued at $122,000 after buying an additional 5,838 shares during the period. Finally, Deutsche Bank AG acquired a new position in Y-mAbs Therapeutics in the 4th quarter valued at approximately $191,000. Institutional investors and hedge funds own 24.80% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Recommended Story: How is Preferred Stock Different from Common Stock?

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.